Buprenorphine Hydrochloride
Generic Name: buprenorphine hydrochloride
Brand Names:
Buprenorphine Hydrochloride
Buprenorphine hydrochloride sublingual tablets are indicated for the treatment of opioid dependence and preferred for induction, used with counseling and psychosocial support.
Overview
Buprenorphine hydrochloride sublingual tablets are indicated for the treatment of opioid dependence and preferred for induction, used with counseling and psychosocial support.
Uses
Indicated for the treatment of opioid dependence and preferred for induction. Should be used with counseling and psychosocial support.
Dosage
Administer sublingually as a single daily dose. Tablets must remain whole and dissolve under the tongue. Maintenance dose typically ranges from 4-24 mg daily, with 16 mg as the recommended target.
Side Effects
Common effects include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, and withdrawal signs. Serious reactions include respiratory depression, hepatic events, and hypersensitivity reactions.
Interactions
Major interactions with benzodiazepines and CNS depressants, CYP3A4 inhibitors/inducers, serotonergic drugs, and MAOIs. Careful monitoring recommended with antiretrovirals.
Warnings
Life-threatening respiratory depression and death risk, especially with benzodiazepines. Pediatric exposure dangers. Neonatal withdrawal syndrome. Dental adverse events including tooth loss. Contraindicated in hypersensitivity to buprenorphine.
Pregnancy
Limited data available. No increased major malformation risk documented from buprenorphine, but untreated opioid addiction in pregnancy is associated with adverse obstetrical outcomes. Buprenorphine passes into breast milk at low levels.
Frequently Asked Questions
What is Buprenorphine Hydrochloride used for?▼
Indicated for the treatment of opioid dependence and preferred for induction. Should be used with counseling and psychosocial support.
What are the side effects of Buprenorphine Hydrochloride?▼
Common effects include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, and withdrawal signs. Serious reactions include respiratory depression, hepatic events, and hypersensitivity reactions.
Can I take Buprenorphine Hydrochloride during pregnancy?▼
Limited data available. No increased major malformation risk documented from buprenorphine, but untreated opioid addiction in pregnancy is associated with adverse obstetrical outcomes. Buprenorphine passes into breast milk at low levels.
What are the important warnings for Buprenorphine Hydrochloride?▼
Life-threatening respiratory depression and death risk, especially with benzodiazepines. Pediatric exposure dangers. Neonatal withdrawal syndrome. Dental adverse events including tooth loss. Contraindicated in hypersensitivity to buprenorphine.
Related Medications
Sibeprenlimab
sibeprenlimab
11 DESCRIPTION VOYXACT contains sibeprenlimab-szsi, an A Proliferation Inducing Ligand (APRIL) blocker and humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. The approximate molecular weight of sibeprenlimab-szsi is 146 kDa. VOYXACT (sibeprenlimab-szsi) injection is a sterile, preservative-free, clear to opalescent, colorless to yellow solution in a single-dose prefilled syringe for subcutaneous use.
Organophosphate Combination
organophosphate combination
*Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Lobster Homarus Americanus
lobster homarus americanus
Dosage form: INJECTION, SOLUTION. Route: PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: LOBSTER, UNSPECIFIED (.1 g/mL). Category: BLA.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.